- £218.75bn
- £236.77bn
- $54.07bn
- 78
- 14
- 98
- 73
REG - AstraZeneca PLC - Lynparza approved in the EU for pancreatic cancer
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Selumetinib granted Japan orphan drug designation
AnnouncementREG - AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Agreement to Supply Europe with COVID-19 Vaccine
AnnouncementREG - AstraZeneca PLC - EMTN Programme Routine Technical Update
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Block listing Interim Review
AnnouncementREG - AstraZeneca PLC - Brilinta obtains additional US approval
AnnouncementREG - AstraZeneca PLC - Lynparza EU CHMP opinion in pancreatic cancer
AnnouncementREG - AstraZeneca PLC - Second Price Monitoring Extn
AnnouncementREG - AstraZeneca PLC - Price Monitoring Extension
AnnouncementREG - AstraZeneca PLC - Imfinzi sustained overall survival in CASPIAN
AnnouncementREG - AstraZeneca PLC - Enhertu DESTINY-Gastric01 results from ASCO 2020
AnnouncementREG - AstraZeneca PLC - Tagrisso unprecedented adjuvant lung cancer data
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Enhertu US orphan designation in gastric cancer
Announcement